Amival0.5 mg+10 mg

Amival is a fixed-dose combination of a phenothiazine antipsychotic (fluphenazine) and a tricyclic antidepressant (nortriptyline), marketed in some countries, including Bangladesh, for short-term symptomatic management of mixed anxiety-depressive states. It is not an FDA-approved product in the United States, and its use should be guided by a registered physician's assessment of the individual patient.

Regionally labeled use (combination product)

• Mild to moderate mixed anxiety and depression, particularly where anxiety and depressive symptoms occur together.
• Emotional disturbance associated with depressive symptoms, including associated sleep disturbance.
• Psychosomatic complaints (e.g., functional gastric symptoms) occurring in the context of mixed anxiety-depression, as an adjunct to overall management.

Evidence from individual components

• Nortriptyline alone is established for relief of symptoms of major depressive disorder.
• Fluphenazine alone is established for management of manifestations of psychotic disorders.

Because this is an older fixed combination, it is generally reserved for cases where combination therapy is specifically judged appropriate rather than used as first-line treatment; single-agent therapy is preferred first-line in most current guidelines for depression and anxiety.

Each tablet contains Fluphenazine (as hydrochloride) 0.5 mg and Nortriptyline (as hydrochloride) 10 mg.

Amival combines a low dose of the phenothiazine antipsychotic fluphenazine with the tricyclic antidepressant nortriptyline in a single tablet. The combination is intended to provide anxiolytic/mild antipsychotic effect together with antidepressant activity for short-term use in mixed anxiety-depressive presentations, under close medical supervision.

Amival belongs to the therapeutic class of Antipsychotic-Antidepressant combination preparations (Phenothiazine derivative + Tricyclic antidepressant, TCA).

Fluphenazine + Nortriptyline combines two agents with complementary central nervous system pharmacology.

Fluphenazine component

Fluphenazine is a piperazine phenothiazine that blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, producing antipsychotic and tranquilizing effects; it also has alpha-adrenergic blocking, antihistaminic, and weak anticholinergic activity.

Nortriptyline component

Nortriptyline is a tricyclic antidepressant that inhibits presynaptic neuronal reuptake of norepinephrine and, to a lesser extent, serotonin, increasing synaptic monoamine availability. It also has anticholinergic, antihistaminic, and alpha-adrenergic blocking properties, which contribute to its side-effect profile.

Amival tablets are taken orally, swallowed whole with water, with or without food, at the times prescribed by the physician. Do not crush or chew unless advised. Avoid alcohol while taking this medicine.

Amival has clinically significant interactions with the following:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use or use within 14 days of an MAOI is contraindicated due to risk of hypertensive crisis and serotonin syndrome.
• Other CNS depressants (alcohol, barbiturates, opioids, benzodiazepines): Additive sedation and risk of respiratory depression.
• QT-interval-prolonging drugs (e.g., certain antiarrhythmics, macrolide/fluoroquinolone antibiotics, other antipsychotics): Additive risk of QT prolongation and arrhythmia, since both components of Amival can affect cardiac conduction.
• Other anticholinergic drugs: Additive anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, confusion).
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine, cimetidine): May significantly increase nortriptyline plasma levels, raising toxicity risk; dose adjustment may be needed.
• Sympathomimetic agents: The nortriptyline component may potentiate the pressor response to adrenaline/noradrenaline-like drugs.

Because Amival combines an antipsychotic and a tricyclic antidepressant, side effects reflect both components.

• Central nervous system: Sedation, drowsiness, extrapyramidal symptoms (tremor, rigidity, akathisia, dystonia), and with prolonged use, tardive dyskinesia (potentially irreversible).
• Anticholinergic: Dry mouth, blurred vision, constipation, urinary retention, confusion (especially in the elderly).
• Cardiovascular: Orthostatic hypotension, tachycardia, and cardiac conduction changes.
• Metabolic/Endocrine: Weight gain, amenorrhea, galactorrhea, sexual dysfunction.
• Rare but serious: Neuroleptic malignant syndrome, agranulocytosis/blood dyscrasia, and (rarely) sudden death - seek immediate medical attention if these occur.

The safety of Amival in pregnancy has not been established. It should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician must be consulted. Use late in pregnancy has been associated, for the antipsychotic component, with neonatal extrapyramidal and/or withdrawal symptoms after delivery. Amival is excreted into breast milk; breastfeeding is generally not recommended during treatment, and a physician should be consulted regarding infant feeding.

Amival carries several important warnings that require close medical supervision.

• Increased mortality in elderly patients with dementia-related psychosis: Antipsychotic medicines, including the fluphenazine component of Amival, are associated with an increased risk of death when used in elderly patients with dementia-related psychosis; this product is not approved for that use.
• Suicidality risk: Antidepressants, including the nortriptyline component of Amival, may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24, especially early in treatment; close monitoring is required.
• Cardiac risk: Use with caution in patients with cardiovascular disease; can affect cardiac conduction and precipitate arrhythmia (see Overdose Effects for cardiotoxicity risk in overdose).
• Tardive dyskinesia and extrapyramidal symptoms: Risk increases with dose and duration of use; periodic reassessment is advised.
• Use with caution in glaucoma, prostatic enlargement/urinary retention, epilepsy or seizure disorder, and hepatic or renal impairment.
• May impair mental and/or physical abilities; caution is advised when driving or operating machinery.
• Avoid abrupt discontinuation after prolonged use; taper under medical supervision.

Overdose of Amival is potentially life-threatening, primarily due to the tricyclic antidepressant component, and can cause cardiac dysrhythmias, QRS widening, severe hypotension, seizures, and profound CNS depression, along with extrapyramidal reactions from the antipsychotic component. If overdose is suspected, seek immediate emergency medical attention or contact a poison control center right away; do not attempt home treatment. Management requires hospital-based cardiac monitoring and supportive care as directed by medical professionals.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Increased risk of death when used for dementia-related psychosis (see Precautions and Warnings); increased sensitivity to sedative, anticholinergic, and hypotensive effects; use lower doses with close monitoring.

Children: Not recommended; safety and efficacy of Amival have not been established in children (see Pediatric Uses).

Pregnancy and lactation: See Pregnancy and Lactation section.

Renal/Hepatic impairment: Contraindicated in severe impairment; use with caution and reduced dose in mild-to-moderate impairment.

Duration of treatment with Amival should be individualized by the prescriber and reviewed periodically, generally for short-term management of an acute mixed anxiety-depressive episode. Prolonged use increases the risk of tardive dyskinesia, so ongoing need should be reassessed regularly, and the drug should not be continued longer than clinically necessary.

Fluphenazine + Nortriptyline is classified as an Antipsychotic (phenothiazine) - Tricyclic Antidepressant (TCA) fixed-dose combination.

Fluphenazine + Nortriptyline acts through two complementary mechanisms. The fluphenazine component blocks postsynaptic dopamine D2 receptors, reducing dopaminergic neurotransmission to produce an antipsychotic/tranquilizing effect. The nortriptyline component blocks presynaptic reuptake of norepinephrine (and to a lesser extent serotonin), increasing their synaptic concentration to produce an antidepressant effect. Both components also have anticholinergic and antihistaminic activity, which contributes to sedative and autonomic side effects.

The safety and efficacy of Amival have not been established in children, and its use in young children is contraindicated (see Contraindications). Antidepressants, including the nortriptyline component, carry a warning of increased suicidal thinking and behavior in children, adolescents, and young adults up to age 24; this combination should not be used in this population outside specialist psychiatric supervision, if at all, and only when no suitable alternative exists.